How has Genmark Diagnostics Forward P/E changed compared to the previous year?

Forward P/E Ratio of Genmark Diagnostics changed from -37.36 to -94.89, representing a 153.97% change. The value is lower than the previous year.

How has Genmark Diagnostics Forward P/E developed historically?

On Eulerpool you can find the complete historical development of Forward P/E Ratio Genmark Diagnostics since 2006 – with annual values, charts, and detailed analysis.

What is the Genmark Diagnostics Forward P/E?

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

How does Genmark Diagnostics Forward P/E compare to the industry average?

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

What is a good Forward P/E?

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Genmark Diagnostics with sector peers and the industry average to assess whether it is attractive.

Genmark Diagnostics Forward P/E

GNMK

Delisted

The Forward P/E Ratio of Genmark Diagnostics (GNMK) as of Jul 31, 2026 is -94.89. In the previous year, Forward P/E Ratio was -37.36 — a change of 153.97% (lower).

Get this data via API

Financial Data API

Forward P/E

-94.89

YoY

153.97%

Last updated: Jul 31, 2026

Forward P/E Ratio of Genmark Diagnostics is 2026 -94.89 . Forward P/E Ratio of Genmark Diagnostics was 2025 -37.36 . It decreases by 153.97% lower compared to the previous year.

Access this data via the Eulerpool API

Docs Get Free API Key

Genmark Diagnostics Stock analysis

What does Genmark Diagnostics do? The company Genmark Diagnostics was founded in 1999 in California, USA. Its goal is to develop and produce diagnostic and testing solutions for the medical and biotechnology industries, with a focus on microfluidic technology. The company offers comprehensive services from the development of diagnostic and testing solutions to the production of devices and systems. Its main business areas are molecular diagnostics, laboratory test automation, and genomics. Genmark Diagnostics provides a variety of test solutions for diseases in the field of molecular diagnostics, as well as automation platforms for laboratory testing and products for genomic analysis. The company's products, such as the ePlex® system, aim to improve the accuracy and speed of medical diagnostics. Genmark Diagnostics is headquartered in Carlsbad, California, USA and has international branches. Its mission is to enhance the accuracy and speed of medical diagnostics worldwide through innovative devices and systems. Genmark Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genmark Diagnostics stock

Forward P/E Ratio of Genmark Diagnostics is -94.89 in 2026.

Access this data via the Eulerpool API

Docs Get Free API Key

Valuation — Genmark Diagnostics

P/E P/S EV/EBIT P/B P/CF P/FCF PEG EV/Revenue EV/EBITDA EV/FCF Earnings Yield FCF Yield Market capitalization Enterprise Value EV/EBIT Forward P/E P/TBV Shareholder Yield Buyback Yield Div.-Adj. PEG EV/OCF

Genmark Diagnostics Forward P/E

Genmark Diagnostics Stock analysis

Frequently Asked Questions about Genmark Diagnostics stock

What is the Genmark Diagnostics Forward P/E 2026?

How has Genmark Diagnostics Forward P/E changed compared to the previous year?

How has Genmark Diagnostics Forward P/E developed historically?

What is the Genmark Diagnostics Forward P/E?

How does Genmark Diagnostics Forward P/E compare to the industry average?

What is a good Forward P/E?

Valuation — Genmark Diagnostics

All Key Metrics — Genmark Diagnostics

Valuation

Income Statement

Margins

Balance Sheet

Cash Flow

Profitability

Leverage

Growth

Dividend

Workforce

Quality

Other